Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Anisodine Hydrobromide for Acute Vertebrobasilar Artery Occlusion Undergoing Endovascular Treatment: A Phase Ib Dose-Escalation Study

Safety and Tolerability of Anisodine Hydrobromide in Patients With Acute Vertebrobasilar Artery Occlusion Undergoing Endovascular Treatment: A Phase Ib, Open-Label, Nonrandomized, 3+3 Dose-Escalation Study

This study is an investigator-initiated Phase Ib clinical trial employing a prospective, single-center, open-label, non-randomized, dose-escalation design. The primary objective is to evaluate the safety and tolerability of anisodine hydrobromide in patients with acute vertebrobasilar artery occlusion undergoing endovascular treatment and to determine the recommended dose for subsequent clinical studies.

Studieoversigt

Status

Ikke rekrutterer endnu

Intervention / Behandling

Detaljeret beskrivelse

This study is an investigator-initiated, prospective, single-center Phase Ib clinical trial designed to evaluate the safety and tolerability of anisodine hydrobromide administered to patients with acute vertebrobasilar artery occlusion undergoing endovascular treatment. The trial adopts an open-label, non-randomized, 3+3 dose-escalation design to identify the maximum tolerated dose (MTD) and determine the recommended Phase II dose (RP2D).

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

24

Fase

  • Fase 1

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 80 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. Age 18 to 80 years.
  2. Diagnosis of acute ischemic stroke.
  3. Time from stroke onset to first dose of study medication ≤24 hours.
  4. Imaging-confirmed acute vertebrobasilar artery occlusion (VBAO), including basilar artery occlusion, bilateral intracranial vertebral artery occlusion, or vertebrobasilar tandem occlusion.
  5. Eligible for and planned to undergo emergency endovascular treatment.
  6. Baseline National Institutes of Health Stroke Scale (NIHSS) score ≥6.
  7. Posterior circulation Alberta Stroke Program Early CT Score (pcASPECTS) ≥6.
  8. No definite extensive irreversible infarction on posterior circulation imaging assessment.
  9. Pre-stroke modified Rankin Scale (mRS) score of 0-1.
  10. Written informed consent obtained from the participant or their legally authorized representative.

Exclusion Criteria:

  1. Evidence of intracranial hemorrhagic disease on head CT, including hemorrhagic stroke, epidural hematoma, subdural hematoma, intraventricular hemorrhage, or subarachnoid hemorrhage.
  2. History of congenital or acquired bleeding disorders, coagulation factor deficiencies, or thrombocytopenic disorders.
  3. Vascular anatomical conditions expected to prevent successful completion of endovascular treatment.
  4. Known severe allergy to iodinated contrast media.
  5. Pregnancy or breastfeeding, or planning to become pregnant during the study period or within 90 days after enrollment.
  6. Known allergy to anisodine hydrobromide or a history of severe intolerance following previous administration.
  7. Concomitant clinical conditions that may be exacerbated by anticholinergic drugs, including but not limited to angle-closure glaucoma, urinary retention, prostatic hypertrophy with difficulty urinating, or paralytic ileus.
  8. Severe cardiac arrhythmias (e.g., tachyarrhythmias requiring electrical cardioversion or recurrent syncope) or hemodynamic instability (e.g., requiring vasopressors or persistent hypotension).
  9. Severe psychiatric disorders, dementia, or impaired consciousness that would prevent the participant from providing informed consent or completing follow-up.
  10. Malignancy or other severe systemic diseases with an expected survival of less than 90 days.
  11. Participation in another interventional clinical study within 30 days before enrollment, or current participation in another interventional clinical study.
  12. Any other condition that, in the investigator's judgment, makes the participant unsuitable for participation in this study.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Enkelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Anisodine Hydrobromide 1.0 mg

Participants receive anisodine hydrobromide 1.0 mg per dose intravenously twice daily for 7 consecutive days in addition to standard endovascular therapy. The first dose is initiated before vascular recanalization; however, administration of the study drug must not delay EVT or other standard endovascular procedures. The study drug is diluted in 0.9% sodium chloride solution and infused over approximately 60 minutes.

Anisodine hydrobromide injection is administered intravenously in addition to standard endovascular therapy for acute ischemic stroke. The investigational drug is diluted in 250 mL of 0.9% sodium chloride solution and infused over approximately 60 minutes. Treatment is given twice daily (BID) for 7 consecutive days, with the first dose initiated prior to vascular recanalization.

In this Phase Ib study, four dose levels (1.0 mg, 1.5 mg, 2.0 mg, and 2.5 mg per dose) are evaluated using a sequential, cohort-based dose-escalation design to assess safety, tolerability, and dose feasibility. All participants receive standard-of-care endovascular therapy according to current clinical guidelines, including mechanical thrombectomy and/or adjunctive procedures as clinically indicated.

Eksperimentel: Anisodine Hydrobromide 1.5 mg

Participants receive anisodine hydrobromide 1.5 mg per dose intravenously twice daily for 7 consecutive days in addition to standard endovascular therapy. The first dose is initiated before vascular recanalization; however, administration of the study drug must not delay EVT or other standard endovascular procedures. The study drug is diluted in 0.9% sodium chloride solution and infused over approximately 60 minutes.

Anisodine hydrobromide injection is administered intravenously in addition to standard endovascular therapy for acute ischemic stroke. The investigational drug is diluted in 250 mL of 0.9% sodium chloride solution and infused over approximately 60 minutes. Treatment is given twice daily (BID) for 7 consecutive days, with the first dose initiated prior to vascular recanalization.

In this Phase Ib study, four dose levels (1.0 mg, 1.5 mg, 2.0 mg, and 2.5 mg per dose) are evaluated using a sequential, cohort-based dose-escalation design to assess safety, tolerability, and dose feasibility. All participants receive standard-of-care endovascular therapy according to current clinical guidelines, including mechanical thrombectomy and/or adjunctive procedures as clinically indicated.

Eksperimentel: Anisodine Hydrobromide 2.0 mg

Participants receive anisodine hydrobromide 2.0 mg per dose intravenously twice daily for 7 consecutive days in addition to standard endovascular therapy. The first dose is initiated before vascular recanalization; however, administration of the study drug must not delay EVT or other standard endovascular procedures. The study drug is diluted in 0.9% sodium chloride solution and infused over approximately 60 minutes.

Anisodine hydrobromide injection is administered intravenously in addition to standard endovascular therapy for acute ischemic stroke. The investigational drug is diluted in 250 mL of 0.9% sodium chloride solution and infused over approximately 60 minutes. Treatment is given twice daily (BID) for 7 consecutive days, with the first dose initiated prior to vascular recanalization.

In this Phase Ib study, four dose levels (1.0 mg, 1.5 mg, 2.0 mg, and 2.5 mg per dose) are evaluated using a sequential, cohort-based dose-escalation design to assess safety, tolerability, and dose feasibility. All participants receive standard-of-care endovascular therapy according to current clinical guidelines, including mechanical thrombectomy and/or adjunctive procedures as clinically indicated.

Eksperimentel: Anisodine Hydrobromide 2.5 mg

Participants receive anisodine hydrobromide 2.5 mg per dose intravenously twice daily for 7 consecutive days in addition to standard endovascular therapy. The first dose is initiated before vascular recanalization; however, administration of the study drug must not delay EVT or other standard endovascular procedures. The study drug is diluted in 0.9% sodium chloride solution and infused over approximately 60 minutes.

Anisodine hydrobromide injection is administered intravenously in addition to standard endovascular therapy for acute ischemic stroke. The investigational drug is diluted in 250 mL of 0.9% sodium chloride solution and infused over approximately 60 minutes. Treatment is given twice daily (BID) for 7 consecutive days, with the first dose initiated prior to vascular recanalization.

In this Phase Ib study, four dose levels (1.0 mg, 1.5 mg, 2.0 mg, and 2.5 mg per dose) are evaluated using a sequential, cohort-based dose-escalation design to assess safety, tolerability, and dose feasibility. All participants receive standard-of-care endovascular therapy according to current clinical guidelines, including mechanical thrombectomy and/or adjunctive procedures as clinically indicated.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Occurrence of Predefined Safety Events Within 8 Days
Tidsramme: Within 8 days after the first administration

The primary safety outcome is the occurrence of predefined safety events within 8 consecutive days after the first administration of the study drug. Predefined safety events include: (1) symptomatic intracranial hemorrhage (sICH), defined as intracranial hemorrhage confirmed by neuroimaging in conjunction with neurological deterioration, operationalized as an increase of at least 4 points in the NIHSS score; (2) death from any cause; and (3) any other serious adverse event (SAE), excluding the foregoing events, that is adjudicated by the Data Monitoring Committee (DMC) to be definitely, probably, or possibly related to the study drug.

Within 8 days after the first administration

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Early Neurological Deterioration
Tidsramme: Within 24 hours after treatment initiation

Early neurological deterioration is defined as worsening in neurological status within 24 hours after treatment initiation. Neurological status is assessed using the National Institutes of Health Stroke Scale (NIHSS), a validated clinical instrument for assessing stroke severity. The NIHSS total score ranges from 0 to 42, with higher scores indicating greater neurological impairment.

Within 24 hours after treatment initiation
Infarct Volume
Tidsramme: Day 8

Infarct volume measured on non-contrast cranial computed tomography (CT) at Day 8, expressed in milliliters (mL).

Day 8
Functional Outcome (Modified Rankin Scale)
Tidsramme: Day 90

Functional outcome assessed using the modified Rankin Scale (mRS) at Day 90. The mRS score ranges from 0 (no symptoms) to 6 (death), with higher scores indicating greater disability. The distribution of mRS scores will be reported.

Day 90
Incidence of Symptomatic Intracranial Hemorrhage
Tidsramme: Within 8 days after the first administration

Incidence of symptomatic intracranial hemorrhage (sICH) confirmed by neuroimaging and accompanied by neurological deterioration, defined as an increase of at least 4 points in the NIHSS score, within 8 days after the first administration of the study drug.

Within 8 days after the first administration
Incidence of Any Intracranial Hemorrhage
Tidsramme: Within 8 days after the first administration

Incidence of any intracranial hemorrhage detected by neuroimaging within 8 days after the first administration of the study drug, regardless of whether neurological deterioration is present.

Within 8 days after the first administration
Incidence of Study Drug-Related Adverse Events
Tidsramme: Within 90 days after the first administration

Incidence of adverse events (AEs) occurring within 90 days after the first administration of the study drug that are considered definitely, probably, or possibly related to anisodine hydrobromide.

Within 90 days after the first administration
Incidence of Study Drug-Related Serious Adverse Events
Tidsramme: Within 90 days after the first administration

Incidence of serious adverse events (SAEs) occurring within 90 days after the first administration of the study drug that are considered definitely, probably, or possibly related to anisodine hydrobromide.

Within 90 days after the first administration
All-Cause Mortality
Tidsramme: Within 90 days after the first administration

All-cause mortality occurring within 90 days after the first administration of the study drug.

Within 90 days after the first administration

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: Yu Feng, MD, PhD, The Affiliated Hospital of Xuzhou Medical University
  • Studieleder: Yanbo Cheng, MD, PhD, The Affiliated Hospital of Xuzhou Medical University

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

20. november 2026

Primær færdiggørelse (Anslået)

20. januar 2027

Studieafslutning (Anslået)

20. januar 2027

Datoer for studieregistrering

Først indsendt

15. november 2026

Først indsendt, der opfyldte QC-kriterier

15. november 2026

Først opslået (Faktiske)

19. november 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

19. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

15. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner